Dynamic Changes in Circulating Methylated Markers in Response to Antitumor Therapy of Rectal Cancer.

Autor: Ponomaryova AA; Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, 634009, Tomsk, Russia. Anastasia-ponomaryova@rambler.ru., Rykova EY; Institute of Cytology and Genetics of the Siberian Branch of the Russian Academy of Sciences, 630090, Novosibirsk, Russia.; Department of Engineering Problems of Ecology, Novosibirsk State Technical University, 630087, Novosibirsk, Russia., Solovyova AI; Department of Biochemistry, Medico-Biological Faculty, Siberian State Medical University, 634050, Tomsk, Russia., Tarasova AS; Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, 634009, Tomsk, Russia., Kostromitsky DN; Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, 634009, Tomsk, Russia., Dobrodeev AY; Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, 634009, Tomsk, Russia., Afanasiev SA; Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, 634009, Tomsk, Russia., Cherdyntseva NV; Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, 634009, Tomsk, Russia.; Faculty of Chemistry, National Research Tomsk State University, 634050, Tomsk, Russia.
Jazyk: angličtina
Zdroj: Journal of gastrointestinal cancer [J Gastrointest Cancer] 2024 Sep; Vol. 55 (3), pp. 1190-1198. Date of Electronic Publication: 2024 Jun 03.
DOI: 10.1007/s12029-024-01066-y
Abstrakt: Background: Rectal cancer (RC) occupies a leading position in the structure of oncological morbidity and mortality. Aberrant methylation of tumor-suppressor genes and hypomethylation of retrotransposons were shown to be detectable in cell-free DNA, circulating in the blood (cfDNA) of cancer patients, indicating the possibility to use them as diagnostic and prognosis markers.
Purpose: Evaluation of the changes in the methylation level of LINE-1 elements and SEPTIN9 and IKZF1 genes in the cell-surface-bound cfDNA (csb-cfDNA) from the blood of RC patients after antitumor therapy at a long-term follow-up.
Methods: Blood samples were obtained from RC patients (n = 25) before treatment, after preoperative chemotherapy (3 courses according to the XELOX scheme), 10-15 days after surgery, and every 3 months during 12 months of dynamic observation. The methylation level of LINE-1, SEPTIN9, and IKZF1 in the csb-cfDNA was evaluated by quantitative methyl-specific PCR.
Results: The LINE-1 methylation level in the csb-cfDNA increased 1.6 times in RC patients after chemotherapy and 3 times after tumor resection versus methylation level before therapy. The SEPTIN9 gene methylation level in the csb-cfDNA decreased by 1.7 times in RC patients after chemotherapy and by 2.3 times after tumor resection compared with the values before the treatment. The IKZF1 gene methylation level decreased by 2 times in RC patients after combined therapy. Notably, all patients with relapses (n = 5) showed an increase in methylation level for the SEPTIN9 and IKZF1 genes and a decrease of methylation level for the LINE-1 elements by 2 times or more in comparison with the level 10-15 days after surgery. There were no changes in the circulating SEPTIN9, IKZF1, and LINE-1 methylation levels during the 12-month follow-up period after the combined therapy of RC patients (n = 20) without relapses.
Conclusion: The results indicate that SEPTIN9, IKZF1, and LINE-1 methylation levels in the csb-cfDNA are potential markers of the effectiveness of antitumor therapy and early detection of relapse in RC patients.
(© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: